ID   KYSE-150
AC   CVCL_1348
SY   KYSE 150; KYSE150; Kyse150; KY150
DR   BTO; BTO:0002427
DR   CLO; CLO_0007129
DR   EFO; EFO_0006627
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 919
DR   BioSample; SAMN03471047
DR   BioSample; SAMN10988383
DR   cancercelllines; CVCL_1348
DR   CCRID; 3101HUMTCHu236
DR   Cell_Model_Passport; SIDM01031
DR   CGH-DB; 278-1
DR   CGH-DB; 9227-4
DR   ChEMBL-Cells; CHEMBL3307840
DR   ChEMBL-Targets; CHEMBL613998
DR   CLS; 305087
DR   Cosmic; 907317
DR   Cosmic; 918525
DR   Cosmic; 929523
DR   Cosmic; 1123338
DR   Cosmic; 1581073
DR   Cosmic; 1876252
DR   Cosmic; 2267699
DR   Cosmic; 2395002
DR   Cosmic; 2650630
DR   Cosmic; 2698434
DR   Cosmic-CLP; 907317
DR   DepMap; ACH-000855
DR   DSMZ; ACC-375
DR   DSMZCellDive; ACC-375
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 907317
DR   GEO; GSM718289
DR   GEO; GSM827545
DR   GEO; GSM887248
DR   GEO; GSM888323
DR   GEO; GSM1670017
DR   IARC_TP53; 21448
DR   JCRB; JCRB1095
DR   LiGeA; CCLE_818
DR   LINCS_HMS; 50025
DR   LINCS_LDP; LCL-1548
DR   PharmacoDB; KYSE150_802_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1348
DR   PubChem_Cell_line; CVCL_1348
DR   Ubigene; YC-B002
DR   Wikidata; Q54900805
RX   PubMed=1728357;
RX   PubMed=7913084;
RX   PubMed=9033652;
RX   PubMed=11092977;
RX   PubMed=15172977;
RX   PubMed=16045545;
RX   PubMed=16832412;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21191746;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
RX   PubMed=36090890;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 13.7 hours (PubMed=1728357); 23 hours (PubMed=25984343); <25 hours (Note=Less when serum amount is increased) (DSMZ=ACC-375).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.41%; Native American=0%; East Asian, North=79.69%; East Asian, South=18.82%; South Asian=0%; European, North=0%; European, South=1.08% (PubMed=30894373).
CC   Discontinued: JCRB; JCRB1095; probable.
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,11
ST   D16S539: 9,11
ST   D18S51: 14
ST   D19S433: 15
ST   D21S11: 30,31
ST   D2S1338: 25
ST   D3S1358: 15,16
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 10,15 (PubMed=25877200)
ST   D8S1179: 15 (DSMZ)
ST   FGA: 21,24
ST   Penta D: 10
ST   Penta E: 12,18
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   49Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   PubMed=1728357; DOI=10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C;
RA   Shimada Y., Imamura M., Wagata T., Yamaguchi N., Tobe T.;
RT   "Characterization of 21 newly established esophageal cancer cell
RT   lines.";
RL   Cancer 69:277-284(1992).
//
RX   PubMed=7913084; DOI=10.1002/ijc.2910580224;
RA   Kanda Y., Nishiyama Y., Shimada Y., Imamura M., Nomura H., Hiai H.,
RA   Fukumoto M.;
RT   "Analysis of gene amplification and overexpression in human
RT   esophageal-carcinoma cell lines.";
RL   Int. J. Cancer 58:291-297(1994).
//
RX   PubMed=9033652; DOI=10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.0.CO;2-C;
RA   Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K.;
RT   "Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b)
RT   genes in 30 esophageal squamous-cell-carcinoma cell lines.";
RL   Int. J. Cancer 70:437-442(1997).
//
RX   PubMed=11092977; DOI=10.1111/j.1349-7006.2000.tb00895.x;
RA   Pimkhaokham A., Shimada Y., Fukuda Y., Kurihara N., Imoto I.,
RA   Yang Z.-Q., Imamura M., Nakamura Y., Amagasa T., Inazawa J.;
RT   "Nonrandom chromosomal imbalances in esophageal squamous cell
RT   carcinoma cell lines: possible involvement of the ATF3 and CENPF genes
RT   in the 1q32 amplicon.";
RL   Jpn. J. Cancer Res. 91:1126-1133(2000).
//
RX   PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172;
RA   Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K.,
RA   Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.;
RT   "Frequent silencing of low density lipoprotein receptor-related
RT   protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in
RT   esophageal squamous cell carcinoma.";
RL   Cancer Res. 64:3741-3747(2004).
//
RX   PubMed=16045545; DOI=10.1111/j.0959-9673.2005.00431.x;
RA   Ban S., Michikawa Y., Ishikawa K.-i., Sagara M., Watanabe K.,
RA   Shimada Y., Inazawa J., Imai T.;
RT   "Radiation sensitivities of 31 human oesophageal squamous cell
RT   carcinoma cell lines.";
RL   Int. J. Exp. Pathol. 86:231-240(2005).
//
RX   PubMed=16832412; DOI=10.1038/sj.bjc.6603255;
RA   Tsunoda S., Okumura T., Ito T., Mori Y., Soma T., Watanabe G.,
RA   Kaganoi J.-i., Itami A., Sakai Y., Shimada Y.;
RT   "Significance of nerve growth factor overexpression and its autocrine
RT   loop in oesophageal squamous cell carcinoma.";
RL   Br. J. Cancer 95:322-330(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21191746; DOI=10.1007/s11684-010-0260-x;
RA   Ji J.-F., Wu K., Wu M., Zhan Q.-M.;
RT   "p53 functional activation is independent of its genotype in five
RT   esophageal squamous cell carcinoma cell lines.";
RL   Front. Med. China 4:412-418(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=36090890; DOI=10.1155/2022/5632744;
RA   Gu Z.-L., Zhu W.-G., Wang W.-W., Xu Y.-Y., Jiang L., Huang J.-S.,
RA   Huang J.;
RT   "Anlotinib inhibits tumor angiogenesis and promotes the anticancer
RT   effect of radiotherapy on esophageal cancer through inhibiting
RT   EphA2.";
RL   J. Oncol. 2022:5632744.1-5632744.11(2022).
//